Search

Cobalamin

SF1126

SF1126 is an integrin-targeted PI3 kinase inhibitor.

Recombinant stabilized RSV B prefusion F antigen

[L49555] Abrysvo was approved for the same indications in the EU in August 2023[L49565] and Canada in December 2023.

Bulevirtide

It was first approved for use in the EU on May 28, 2020; bulevirtide has been granted PRIME scheme eligibility and Orphan Drug Designation by the European Medicines Agency.

Metronidazole benzoate

Shark liver oil

Shark oil is a rich source of alkylglycerols and squalene, with relatively low amounts of n-3 polyunsaturated fatty acids.

ALKS 27

Study showed that ALKS 27 was well-tolerated over a wide dose range, with no dose-limited effects observed.

NUC B1000

On January 11, 2008, it was announced that NUC B1000 was entering a phase 1 human safety study of its experimental treatment for chronic Hepatitis B virus (HBV) infection. … NUC B1000 is an expressed interfering RNA (eiRNA)- based product consisting of a plasmid DNA construct designed to produce four short interfering RNA (siRNA) molecules, formulated with a proprietary cationic-lipid

Technetium Tc-99m arcitumomab

Reduced Fab fragment of the murine IgG1 monoclonal antibody IMMU-4 (also called NP-4) with specificity for carcinoembryonic antigen (CEA) covalently labeled with Technitium 99.

Cintredekin besudotox

Cintredekin besudotox is made from a human protein, Interleukin 13 (IL13), linked to a bacterial toxin, _Pseudomonas exotoxin_ (PE). The IL13 portion binds to receptors on the tumor.